Drug Trial Radar · NCT03439124
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
Last checked: Nov 20, 2026Latest source record: May 12, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Nov 27, 2017
Primary completion
Mar 16, 2020
Study completion Mar 16, 2020
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Feb 20, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 3 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired bacterial pneumonia (HAP) or community-acquired bacterial pneumonia (CAP) requiring hospitalization, and requiring intravenous (IV) antibiotic therapy.
Conditions
- Community-acquired Pneumonia (CAP)
- Hospital-acquired Pneumonia (HAP)
Interventions
ceftobiprole medocarilDrug
Ceftobiprole medocaril was administered at age-adjusted doses (10, 15 or 20 mg/kg) and infusion durations (2 or 4 hours) every 8 hours. The maximum dose, regardless of body weight, was 500 mg ceftobiprole every 8 hours (maximum total daily dose of 1500 mg ceftobiprole). After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment.
IV standard-of-care cephalosporinDrug
Ceftriaxone was administered at 50 to 80 mg/kg IV as a single daily dose, up to a maximum dose of 2 g/day. The actual dose of ceftriaxone within this dose range was determined by the blinded investigator prior to first study drug administration and was not modified during subsequent study days. After a minimum of 3 days of IV treatment, patients with sufficient improvement in disease signs and symptoms could be switched to an age-appropriate oral antibiotic to complete a total minimum of 7 days and a total maximum of 14 days' antibiotic treatment. At the discretion of the blinded investigator, patients received vancomycin at a dose of 10 to 15 mg/kg IV every 6 hours, up to a maximum dose of 2 g/day, in addition to the IV standard-of-care cephalosporin when MRSA was suspected or confirmed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse EventsTime frame: Analysis of AEs assessed during the first 3 days of IV therapy and while on IV, a median of 7 days
Locations
19 sites in 4 countries. Site status is shown where the registry gives one.
University Multiprofile Hospital for Active Treatment "Dr. Georgi Stranski"
Pleven, Bulgaria
University Multiprofile Hospital for Active Treatment "Sveti Georgi"
Plovdiv, Bulgaria
Multiprofile Hospital for Active Treatment
Rousse, Bulgaria
University Multiprofile Hospital for Active Treatment "Aleksandrovska"
Sofia, Bulgaria
Amtel Hospital First Clinical LLC
Tbilisi, Georgia
LTD High Technology Medical Center University Clinic
Tbilisi, Georgia
JSC Evex Hospitals 1
Tbilisi, Georgia
JSC Evex Hospitals 2
Tbilisi, Georgia
Tbilisi State Medical University G. Zhvania Pediatric Academic Clinic
Tbilisi, Georgia
Ltd Tbilisi Pediatric Private Clinic
Tbilisi, Georgia
Principal SMO Ltd.
Baja, Hungary
Semmelweis University
Budapest, Hungary
Central Hospital of Southern Pest National Institute of Hematology and Infectious Diseases
Budapest, Hungary
Bekes County Central Hospital
Gyula, Hungary
Kanizsai Dorottya Hospital
Nagykanizsa, Hungary
Fejer County St. Gyorgy University Teaching Hospital
Székesfehérvár, Hungary
Torokbalint Pulmonology Institute
Törökbálint, Hungary
Alessandrescu-Rusescu National Institute for Mother and Child Health
Bucharest, Romania
Sf. Maria" Children's Emergency Clinical Hospital
Iași, Romania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.